Findings

What does this study add?

• The average length of time a patient was on erenumab prior to switching to galcanezumab was 7 months, and the average length of time a patient was on galcanezumab was 4.8 months.
• 51% of patients reported improvement with erenumab versus 50% of patients on galcanezumab.
• 35% of patients reported no improvement on erenumab compared to 29% of patients who reported no improvement on galcanezumab.
• An equal amount of patients responded to erenumab but not galcanezumab (n=9) as to galcanezumab but not erenumab (n=9).
• Lack of efficacy was the main reason for discontinuation of erenumab or galcanezumab treatment, followed by side effects and insurance difficulties.
• Constipation was the most commonly reported side effect in the erenumab group (35%) and injection site reactions were most common in the galcanezumab group (10%).